Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 7/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880298 | 1.00 | KDM4E (0.52) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL18905641 | 0.84 | TSHR (0.48) | KDM4ECYP3A4MAPTTSHRAPP | |
| SCHEMBL1697126 | 0.84 | MAPT (0.64) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL17469912 | 0.82 | PARP1 (0.41) | NOS1NOS2HTR7TSHRAPP | |
| Hydrochloric Acid SCHEMBL3273205 | 0.81 | MAPT (0.68) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL18392541 | 0.80 | APP (0.41) | PRMT6NOS1NOS2TSHRAPP | |
| SCHEMBL15697692 | 0.80 | SLC2A1 (0.46) | TSHRAPP | |
| SCHEMBL3617649 | 0.80 | RAPGEF4 (0.55) | MAPTTSHR | |
| SCHEMBL22163747 | 0.79 | CYP1A2 (0.47) | MAPTHTR7APP | |
| SCHEMBL2291506 | 0.78 | HTR6 (0.50) | CYP3A4PRMT6NOS1NOS2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | INTERVET INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2020002238-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INTERNATIONAL B.V. (NL) | 2020-01-02 | — | — | WO | disclosed |
| US-20190352256-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | INTERVET INC. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-2941426-B1 | SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9764040-B2 | Spliceostatin analogs and methods for their preparation | PFIZER INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170153526-A1 | REFLECTIVE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20170014523-A1 | SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION | PFIZER (US) | 2017-01-19 | — | — | US | disclosed |
| US-9169264-B2 | Spliceostatin analogs and methods for their preparation | PFIZER INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | HEXD, SORD, SDHA | KDM4E 4069/4885CYP3A4 875/4885MAPT 3946/4885 |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, PPARD | KDM4E 4510/4885CYP3A4 1430/4885MAPT 2194/4885 |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | SORD, HEXD, SDHA | KDM4E 3794/4885CYP3A4 1092/4885MAPT 4092/4885 |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | KDM4E 2310/4885CYP3A4 3946/4885MAPT 4257/4885 |
| US-20190352256-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | HEXD, SORD, SDHA | KDM4E 4069/4885CYP3A4 875/4885MAPT 3946/4885 |
| US-20170014523-A1 | SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION | SF3B5, SF3B1, SNRPA1 | KDM4E 1288/4885CYP3A4 4424/4885MAPT 4021/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | KDM4E 2464/4885CYP3A4 1094/4885MAPT 4348/4885 |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, BRD1 | KDM4E 4293/4885CYP3A4 2376/4885MAPT 1823/4885 |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | PIGS, BTD, PPARD | KDM4E 4185/4885CYP3A4 1989/4885MAPT 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.